Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference45 articles.
1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
2. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
3. Hales C, Carroll M, Fryar C, Centers for Disease Control and Prevention. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. https://www.cdc.gov/nchs/data/databriefs/db360-h.pdf. Published 2020. Accessed 8 Feb 2021.
4. Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76:908–16.
5. Zulkifly H, Lip GYH, Lane DA. Epidemiology of atrial fibrillation. Int J Clin Pract. 2018;72:e13070.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献